Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62).
作者信息
Kawada Tomoyuki
机构信息
Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
出版信息
Diabetes Metab J. 2022 Jul;46(4):663-664. doi: 10.4093/dmj.2022.0131. Epub 2022 Jul 27.
Abstract
摘要
相似文献
1
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂联合治疗2型糖尿病的临床疗效：真实世界研究（《糖尿病与代谢杂志》2022年；46: 658-62）
Diabetes Metab J. 2022 Jul;46(4):663-664. doi: 10.4093/dmj.2022.0131. Epub 2022 Jul 27.
2
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂联合治疗2型糖尿病的临床疗效：真实世界研究（《糖尿病与代谢杂志》2022年；46: 658 - 62）
Diabetes Metab J. 2022 Jul;46(4):665-666. doi: 10.4093/dmj.2022.0166. Epub 2022 Jul 27.
3
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂之间糖尿病视网膜病变的风险（《糖尿病代谢杂志》2023年；47:394-404）
Diabetes Metab J. 2023 Jul;47(4):573-574. doi: 10.4093/dmj.2023.0188. Epub 2023 Jul 27.
4
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂之间糖尿病视网膜病变的风险（《糖尿病与代谢杂志》2023年；47:394-404）
Diabetes Metab J. 2023 Jul;47(4):571-572. doi: 10.4093/dmj.2023.0164. Epub 2023 Jul 27.
5
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.在 2 型糖尿病中应用胰高血糖素样肽-1 受体激动剂联合钠-葡萄糖协同转运蛋白 2 抑制剂的实用考量和原理。
Can J Diabetes. 2021 Apr;45(3):291-302. doi: 10.1016/j.jcjd.2020.09.005. Epub 2020 Sep 14.
6
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖共转运蛋白-2 抑制剂及其联合应用对 2 型糖尿病患者内皮糖萼、动脉功能和心肌做功指数的影响：12 个月治疗后的结果。
J Am Heart Assoc. 2020 May 5;9(9):e015716. doi: 10.1161/JAHA.119.015716. Epub 2020 Apr 24.
7
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂对伴有肾功能损害的 2 型糖尿病患者的影响。
Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120971220. doi: 10.1177/1479164120971220.
8
The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.GLP-1 受体激动剂和 SGLT2 抑制剂在 U-500 胰岛素常规治疗患者中的作用。
Ann Pharmacother. 2019 Nov;53(11):1111-1116. doi: 10.1177/1060028019857557. Epub 2019 Jun 19.
9
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.基于人群队列研究的 2 型糖尿病患者胰高血糖素样肽-1 受体激动剂与钠-葡萄糖共转运蛋白 2 抑制剂的心血管比较效果。
Diabetes Obes Metab. 2022 Aug;24(8):1623-1637. doi: 10.1111/dom.14741. Epub 2022 May 25.
10
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
本文引用的文献
1
Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.糖尿病和代谢综合征中 SGLT-2 抑制剂和 GLP-1 激动剂相关的血脂谱变化。
Metab Syndr Relat Disord. 2022 Aug;20(6):321-328. doi: 10.1089/met.2022.0004. Epub 2022 Apr 22.
2
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.在 2 型糖尿病中，使用 SGLT2 抑制剂、GLP-1 受体激动剂及其联合治疗进行心血管和心力衰竭事件的一级预防。
Diabetes Care. 2022 Apr 1;45(4):909-918. doi: 10.2337/dc21-1113.
3
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂在心血管和肾脏保护方面的作用：一种超越降血糖作用的治疗方法。
Eur J Intern Med. 2022 Feb;96:26-33. doi: 10.1016/j.ejim.2021.11.008. Epub 2021 Nov 17.
4
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂联合治疗 2 型糖尿病的临床疗效：真实世界研究。
Diabetes Metab J. 2022 Jul;46(4):658-662. doi: 10.4093/dmj.2021.0232. Epub 2021 Nov 8.
5
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.在接受胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白 2 抑制剂治疗的糖尿病患者中，死亡和心血管事件风险降低：两项意大利队列的真实世界研究。
Diabetes Obes Metab. 2021 Jul;23(7):1484-1495. doi: 10.1111/dom.14361. Epub 2021 Mar 15.
Zotero 插件